Ismaris Bouchard Email

VP, Finance & Reporting . Catalyst Pharmaceuticals

Current Roles

Employees:
173
Revenue:
$34.8M
About
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis (MuSK-MG) and spinal muscular atrophy (SMA) Type 3. Catalyst's new drug application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was recently approved by the U.S. Food & Drug Administration ("FDA"), and Firdapse is now commercially available in the United States. Prior to its approval, Firdapse for LEMS had received breakthrough therapy designation and orphan drug designation from the FDA. Firdapse is currently being evaluated in clinical trials for the treatment of CMS, MuSK-MG and SMA Type 3 and has received Orphan Drug Designation from the FDA for CMS and myasthenia gravis. Firdapse (amifampridine) 10 mg tablets is the first and only approved drug in Europe for the symptomatic treatment in adults with LEMS.
Catalyst Pharmaceuticals Address
355 Alhambra Circle
Coral Gables, FL
United States
Catalyst Pharmaceuticals Email

Past Companies

Catalyst Pharmaceuticals, Inc.VP, Finance & Reporting
Catalyst Pharmaceuticals, Inc.Director of Financial Reporting
PwCAssurance Manager

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.